E xhibit 99.1 Flamel Technologies Announces Second Quarter of Fiscal Year 2014 Results Company received FDA Approval of Vazculep on

Flamel Technologies Announces Second

Quarter of Fiscal Year 2014 Results

Company received FDA Approval of Vazculep

Conference call with management to

take place at 10:00 am ET on July 29, 2014

Lyon, France - July 29, 2014

- Flamel Technologies (NASDAQ: FLML) today announced its financial results for the second quarter of fiscal year 2014. Highlights

from the quarter include:

"We are pleased that the FDA listed

clat Pharmaceuticals as the only supplier of neostigmine methylsulfate as of June 19th. We have been in frequent

communication with the FDA with regard to Bloxiverz, and look forward to learning more about any specific actions in the near future,"

said Mike Anderson, Chief Executive Officer of Flamel.

"Additionally, we continue to execute

on our strategy with FDA's recent approval of Vazculep," added Mr. Anderson. "Our prompt resubmission of our

NDA for Vazculep and the FDA's subsequent approval ahead of the scheduled PDUFA date is an example of the Company's

ability to work effectively and positively with the FDA and other third parties in order to execute our business plan."

We continue to make progress on our proprietary

pipeline, including the clinical testing of sodium oxybate and other compounds using our Micropump , LiquiTime , Trigger

Lock , and Medusa drug delivery platforms. Continued prioritization of these programs and investments in our internal

infrastructure will facilitate high quality and timely execution on our major proprietary pipeline products throughout 2014 and

Flamel's Second Quarter Results

Flamel reported total revenues during the

second quarter of 2014 of $8.1 million, an increase of $2.5 million in revenues compared to the prior year period. Product sales

and services revenues in the second quarter of 2014 of were $4.1 million, compared to $2.2 million in the prior year quarter, principally

due to sales of Bloxiverz, which was not launched in the second quarter of 2013. On a sequential basis, second quarter 2014 revenues

of $8.1 million were down from $9.2 million in the first quarter of 2014, due to a leveling off of Bloxiverz sales after a spike

in sales in the first quarter when two suppliers of unapproved neostigmine methylsulfate were off the market for a portion of the

Costs of goods and services sold for the

second quarter of 2014 were $1.6 million compared to $1.3 million in the second quarter of 2013, principally due to cost of sales

of Bloxiverz. Research and development costs in the second quarter of 2014 totaled $6.7 million versus $7.3 million in the prior

year period. Selling, general and administrative costs were $4.3 million in the second quarter of 2014 versus $2.7 million in the

second quarter of 2013. This increase resulted from the cost of post-marketing studies requested by the FDA and increased legal

costs. Amortization of R&D assets associated with the development of Bloxiverz was $2.9 million in the second quarter of 2014.

Total net interest income was $94,000 in

the second quarter of 2014 compared to interest expense of $640,000 in the second quarter of 2013. Interest expense was largely

eliminated with the Company's repayment of nearly all of its debt and lines of credit with a portion of the net proceeds

from its offering of 12.4 million ADSs in mid-March 2014.

Net loss for the second quarter of 2014

was $21.1 million versus net loss of $32.8 million in the year-ago period. Earnings per share (both basic and diluted) was $(0.55)

in the second quarter of 2014 versus $(1.29) in the second quarter of 2013.

Adjusted net loss for the second quarter

of 2014 was $4.9 million versus an adjusted net loss of $4.5 million in the second quarter of 2013. Adjusted loss per share (both

basic and diluted) was $(0.13) in the second quarter of 2014 compared to an adjusted loss per share of $(0.18) in the prior year

The Company's cash position as of

June 30, 2014 was $77.9 million.

Flamel is disclosing non-GAAP financial

measures when providing financial results, including adjusted net loss. Flamel believes that an evaluation of its ongoing operations

(and comparison of current operations with historical and future operations) would be difficult if the disclosure of its financial

results were limited to financial measures prepared only in accordance with generally accepted accounting principles (GAAP) in

the U.S. In addition to disclosing its financial results in accordance with GAAP, Flamel is disclosing certain non-GAAP results

that exclude fair value remeasurements, impairment of intangible assets, amortization expense of intangible assets and effects

of accelerated reimbursement of certain debt instruments and include operating cash flows associated with the acquisition liabilities

and Royalty Agreements, in order to supplement investors' and other readers' understanding and assessment of the Company's financial

performance. The Company's management uses these non-GAAP measures internally for forecasting, budgeting and measuring its operating

performance. Investors and other readers are encouraged to review the related GAAP financial measures and the reconciliation of

non-GAAP measures to their most closely applicable GAAP measure set forth below and should consider non-GAAP measures only as a

supplement to, not as a substitute for or as a superior measure to, measures of financial performance prepared in accordance with

Below is a reconciliation of GAAP net losses

attributable to Flamel and diluted GAAP losses per share to adjusted net losses attributable to Flamel and adjusted diluted losses

per share for the three months and six months ended June 30, 2014 and 2013 (in thousands except per share amounts).

A conference call to discuss these results

and other updates is scheduled for 10:00 AM ET on Tuesday, July 29, 2014. A question and answer period will follow management's

prepared remarks. To participate in the conference call, investors are invited to dial 888-428-9490 (U.S.) or 1+719-325-2376

(international). The conference ID number is 1681810. The conference call webcast may be accessed at www.flamel.com. A replay

of the webcast will be archived on Flamel's website for 90 days following the call.

About Flamel Technologies. Flamel

Technologies SA's (NASDAQ: FLML) business model is to blend high-value internally developed products with its leading drug delivery

capabilities. The company markets Bloxiverz (neostigmine methylsulfate) in the USA and manufactures Micropump-based microparticles

under FDA-audited GMP guidelines for Coreg CR (carvedilol phosphate), marketed in the USA by GlaxoSmithKline. The Company

has a proprietary pipeline of niche specialty pharmaceutical products, while its drug delivery platforms are focused on the goal

of developing safer, more efficacious formulations of drugs to address unmet medical needs. Its pipeline includes chemical and

biological drugs formulated with its Micropump (and its applications to the development of liquid formulations LiquiTime

and of abuse-deterrent formulations Trigger Lock ) and Medusa proprietary drug delivery platforms. Several Medusa-based

products have been successfully tested in clinical trials. The Company is headquartered in Lyon, France and has operations in

St. Louis, Missouri, USA, and manufacturing facilities in Pessac, France. Additional information may be found at www.flamel.com.

This release contains "forward-looking

statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including certain plans, expectations,

goals and projections regarding financial results, product developments and technology platforms. All statements that are not clearly

historical in nature are forward-looking, and the words "anticipate," "assume," "believe," "expect,"

"estimate," "plan," "will," "may," and similar expressions are generally intended to identify

forward-looking statements. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond

our control that could cause actual results to differ materially from those contemplated in such forward-looking statements. These

risks include risks that the launch of Bloxiverz will not be as successful as anticipated; our ability to bring other R&D projects

of the former clat Pharmaceuticals to market may be unsuccessful; FDA may not take action on the status of unapproved versions

of neostigmine still on the market; clinical trial results may not be positive or our partners may decide not to move forward;

products in the development stage may not achieve scientific objectives or milestones or meet stringent regulatory requirements;

products in development may not achieve market acceptance; competitive products and pricing may hinder our commercial opportunities;

we may not be successful in identifying and pursuing opportunities to develop our own product portfolio using Flamel's technology;

and the risks associated with our reliance on outside parties and key strategic alliances. These and other risks are described

more fully in Flamel's Annual Report on Form 20-F for the year ended December 31, 2013 that has been filed with the Securities

and Exchange Commission (SEC). All forward-looking statements included in this release are based on information available at the

time of the release. We undertake no obligation to update or alter our forward-looking statements as a result of new information,

future events or otherwise.

Condensed Consolidated Statements of

(Amounts in thousands, except per share